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Background: Vitamin D insufﬁciency is common in cystic ﬁbrosis despite daily
supplementation. There remains no consensus on an effective high-strength sup-
plementation protocol. A high-dose colecalciferol (D3) supplementation regimen
was instigated at our Adult CF Unit in 2010. Patients with low vitamin D(25OHD
<75 nmol/l) were treated with 100,000IU oral colecalciferol once. 25OHD levels
should be rechecked 2−4 weeks post-treatment.
Aim: Effectiveness of high-dose vitamin D supplementation at optimising vitamin D
status was audited.
Methods: Case records were retrospectively reviewed between Apr-Jun 2011.
Patient characteristics, supplementation and 25OHD levels were analysed.
Results: The supplementation protocol was followed for 38 (84%) of the audited
45 cases of colecalciferol administration. Repeat 25OHD levels were available for
28 (62%) which were included in further analysis. Median baseline 25OHD was
52.5 nmol/l(5−68). This increased to 75.5 nmol/l (5–106) post-treatment(p = 0.000).
15 cases (54%) achieved target 25OHD(75 nmol/l). A negative relationship existed
between baseline 25OHD and change in 25OHD(rs = −0.479; p = 0.01). Baseline
25OHD was not independently predicted by pancreatic status however the post-
treatment change in 25OHD was(p = 0.031). Pancreatic sufﬁcient patients(n = 4)
had a greater and more consistent change in their 25OHD levels than insufﬁcient
patients(n = 24).
Conclusion: Colecalciferol 100,000IU enabled most patients to achieve optimal
25OHD levels being most effective in those with the lowest baseline 25OHD.
Persistent vitamin D insufﬁciency and the practicality of supplementation remain a
concern. Vitamin D absorption is a predictor of treatment response.
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Objectives: Prolonged low vitamin D status is associated with poor bone health and
suboptimal levels are prevalent amongst CF adults. Although European guidelines
suggest a minimum D3 level of 50 nmol/L, there is a lack of clarity regarding
supplementation. To look at this further, we assessed the vitamin D status of
206 patients (median age 26 years [IQR 12], 161 pancreatic insufﬁcient, 116 males)
at annual screen and devised a new treatment algorithm.
Methods: Vitamin D3 levels were collated with clinical state and the patient’s
treatment reviewed.
Results: Vitamin D3 levels ranged from <5.0 to 154.1 nmol/L (median 48.4 [51.1]),
and 50 patients (24%) were classed as deﬁcient (<25 nmol/L), 58 (28%) insufﬁcient
(25−50 nmol/L) and 98 (48%) as sufﬁcient (50 nmol/L). Based on these results,
a treatment algorithm was devised (table).
Conclusions: Suboptimal vitamin D levels were found in over half our patients.
The new treatment algorithm will enable better control of vitamin D3 status and
provides a logical treatment plan, with an escalation of therapy if levels do not
improve.
Vitamin D Treatment Algorithm (Summary)
Stage 1 Stage 2 Stage 3 Stage 4
Status Treatment Review Treatment Review Treatment Review Treatment
Deﬁcient cholecalciferol
50,000IU
once/wk
8 weeks cholecalciferol
50,000IU
twice/wk
8 weeks Refer to Bone
Specialist
Team
- -
Insufﬁcient Calcichew D3
Forte b.d
4−5 months cholecalciferol
50,000IU
once/wk
8 weeks cholecalciferol
50,000IU
twice/wk
8 weeks Refer
to Bone
Specialist
Team
